US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)

Print Friendly, PDF & Email

MEANT TO TREAT DAMAGED MITOCHONDRIAL MEMBRANES: LOS ALTOS, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) — Retrotope announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for its chemically-modified polyunsaturated fatty acid drug (RT001) for the treatment of Progressive SupraNuclear Palsy (PSP). Physicians collaborating with Retrotope […]